title: Theranostic nanoemulsions: codelivery of hydrophobic drug and hydrophilic imaging probe for cancer therapy and imaging.
abstract: OBJECTIVE
  To develop a theranostic nanoemulsion (TNE) that can codeliver the conjugates of a hydrophobic drug paclitaxel (PTX) and a hydrophilic imaging probe sulforhodamine B (SRB).
  
  
  METHODS
  The TNE was established using core-matched technology, and can achieve high encapsulation efficiency and synchronized release of the loaded cargo. It has been examined for a correlation between the dynamic uptake of PTX and the intensity of SRB imaging signal in different organs.
  
  
  CONCLUSIONS
  Our data demonstrate that the TNE, with improved circulation time, increases therapeutic efficacy and imaging efficiency in both drug-sensitive and drug-resistant cancer. The TNE could not satisfy the demand of visual diagnosis in the living animal because of interference. We therefore formulated a long-circulating theranostic nanoemulsion (LCTNE). Results showed that the LCTNE can meet imaging requirements in vivo.
  
  
  CONCLUSIONS
  The LCTNE plays a good therapeutic and diagnostic role for subcutaneous tumors in the living animal.
authors.affiliation: Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7571, USA.
authors.forename: Xinggang
authors.initials: X
authors.lastname: Yang
authors.forename: Dun
authors.initials: D
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Ma
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zhao
authors.forename: John K
authors.initials: JK
authors.lastname: Fallon
authors.forename: Dan
authors.initials: D
authors.lastname: Liu
authors.forename: Xian Emma
authors.initials: XE
authors.lastname: Xu
authors.forename: Yongjun
authors.initials: Y
authors.lastname: Wang
authors.forename: Zhonggui
authors.initials: Z
authors.lastname: He
authors.forename: Feng
authors.initials: F
authors.lastname: Liu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000737:chemistry*; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008819:Mice, Nude; D050997:Nanomedicine / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012235:Rhodamines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014810:Vitamin E / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D012235:Rhodamines; D014810:Vitamin E; C022027:lissamine rhodamine B; D017239:Paclitaxel
keywords: core-matched technology; live animal imaging; long-circulating theranostic nanoemulsion; paclitaxel; sulforhodamine B; synchronous release; theranostic nanoemulsions